logo
  

Medtronic To Launch Study For Implantable Tibial Neuromodulation Therapy In Bladder Incontinence

Medtronic plc (MDT) announced FDA approval to proceed with an investigational device exemption trial to evaluate its implantable tibial neuromodulation device — a therapy designed to provide relief from symptoms of bladder incontinence.

The TITAN 1 Feasibility Study is a prospective, multicenter, feasibility study to characterize the procedure for the implantable tibial neuromodulation device in subjects with bladder incontinence. Medtronic said twenty patients from eight sites in the U.S. will receive a device and will be followed for 12 months. Enrollment is anticipated to begin in May 2021.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
When Can We Expect Starlink to Go Public? This question got an answer from Tesla and SpaceX CEO Elon Musk, who said he will only publicly list SpaceX's satellite internet service Starlink when its revenue is more predictable. Musk was responding to a users tweet, "Any thoughts on Starlink IPO we would love to invest in the future. Any thoughts on first dibs for Tesla retail investors?" John David McAfee, who founded the antivirus software company McAfee Associates, has been found dead in a prison cell in Spain shortly after a Spanish court agreed to extradite him to the US to face tax evasion charges, multiple reports said. He was arrested in Spain in October 2020 after being accused of failing to file tax returns for four years. While reporting financial results for the first quarter of fiscal 2022 on Thursday, drugstore chain Rite Aid Corp. (RAD) initiated its adjusted loss and total revenue guidance for the full-year 2022, below analysts' estimates. For fiscal 2022, the company now projects an adjusted loss in a range...
Follow RTT